Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Yuekang Pharmaceutical: Subsidiary YKYY018's inhalation aerosol therapy for the treatment and prevention of human parainfluenza virus infection approved for FDA clinical trials
Yuekang Pharmaceutical announced that its wholly-owned subsidiary, Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd., recently received a letter from the U.S. Food and Drug Administration regarding the approval of the clinical trial application for YKYY018 nebulized inhalation solution for the treatment and prevention of human metapneumovirus, with IND number 180432. YKYY018 nebulized inhalation solution is an internationally original membrane fusion inhibitor drug independently developed by the company based on a full-process AI platform, and has received approval from both the FDA and the National Medical Products Administration for conducting clinical trials aimed at the prevention and treatment of respiratory syncytial virus infections.